HEMP OIL CAPITAL INVESTMENT



Why Hemp

- Hemp can help resolve the opioid crisis by providing alternative, non-addictive body positive help for pain
- CBD (Cannabidiol) extracted from hemp has enormous and proven medical benefits it can change people's lives.
- Hemp is a Business to Business focused marketplace vs. marijuana which is Business to Consumer focused
- Hemp has 50,000 industrial uses, including CBD extract, electronics, fiber, textiles, building material, etc.
- The hemp oil and hemp product market has grown by 10X in the last year and is expanding exponentially.
- CBD oil from hemp is the most expensive oil in the world at \$4,500/liter \$8,000/liter.



our business

Industrial hemp banking is legal and available in All 50 states including retail POS – CBD Oil sales are legal in all 50 states Industrial Hemp has ~0% THC (the psychoactive component in marijuana)

Investment Business Structure - Vertical Integration

4 segments (seed to sale): [1] Real Estate – [2] Cultivation/Processing – [3] Manufacturing – [4] Distribution/Retail

- [1] Real Estate
- [2] Seeds & Clones
 - Cultivation/Harvesting By Farmers
 - Drying
 - Extraction
 - CBD Oil/Distillates/Isolates/Terpenes
 - Testing/Quality Control
- [3] Manufacturing
 - Scientific Quality Control
 - Testing
 - Dosage & Treatment Control
 - Patented Products
- [4] Distribution/Retail
 - Global Sales Channels

(Greenhouses/Processing Facilities/Manufacturing) (Revenue sharing with Farmer – insures material supply)

(Dryers distributed within 2 hour drive of farmers) (Co-located with Dryers - centralized)

(At every extraction facility) (Co-located with Extraction - centralized)

(Primary Laboratory) (White label & proprietary branding)

our bodies

Receptors are found

on cell surfaces

The Human Endocannabinoid System

CB1 receptors CBN is known to "fit" like lock and key into a are concentrated network of existing receptors. The Endocannabinoid in the brain and central System exists to receive cannabinoids produced inside nervous system but also the body called "Anadnamine" and "2-Arachidonylsparsely populates other glycerol." Stimulating the ECS with plant-based parts of the human body. cannabinoids restores balance and helps maintain symptoms CB1 CBD does not directly "fit" CB1 CBD or CB2 receptors but has powerful indirect effects still being studied. Cannabinoid Receptor Presynaptic (sending neuron) ousmitters CB2 CB2 receptors are mostly in the perepheral organs especially cells associated with the immune system. Lipid Precursors (fat cells)

50,000 uses



market

- Hemp is targeted to expand to a \$22 billion market segment by 2020 according to the Chicago Board of Trade
- Presently the Canadian market which has just allowed cannabis companies to go public is putting multiples of 120x – 180X earnings - the US market is 10X that of the Canadian market
- Bayer just bought Monsanto for \$65 Billion principally for its Hemp business




market

US and Global Cannabis markets are projected to reach \$20B and \$31B

by 2021, respectively


92% of states have some • form of legalized cannabis

US



hemp market

Grown and Sold through a Marihuana Supply Chain Vs. Grown and sold through a Hemp Supply Chain





prohibition ends

The sale and distribution of CBD Oil from hemp is legal in all 50 states (if it contains, no THC) – if it contains THC it is legal in 15 states.

The FDA has moved Hemp to a Level 5 drug making it an equivalent to Motrin AC .

markets

Currently operating in three states with leased facilities awaiting licenses or permits in additional markets



Current	Expected	Expected
Dispensary	Dispensaries	Market
Market	At Maturity	Size
450	2,500	\$8.0
dispensarie	s dispensaries	billion

Oregon

California

562 600 dispensaries dispensaries

\$0.5 billion

Illinois

1,000 54 dispensaries dispensaries

\$2.5 billion

Massachusetts

800 31 dispensaries dispensaries

\$1.5 billion

New Jersey

1,000 6 dispensaries dispensaries

\$2.0 billion

Michigan

215 1,200 dispensaries dispensaries

\$2.0 billion

by 2020

Planned State Penetrations by Direct Operations, LBO or Acquisition



	Adult	Tourist	License
	Population	Population	Market
New York	15	173	Limited
	million	million	Licenses
Nevada	2	32	Limited
	million	million	Licenses
Michigan	7	10	Limited
	million	million	Licenses
Florida	16	83	Limited
	million	million	Licenses
Ohio	8	43	Limited
	million	million	Licenses
Pennsylvania	9	128	Limited
	million	million	Licenses

highlights



Technology Driven

Proprietary 28 patents (4 issues, 24 pending issues) that allow the creation of proprietary extracts and CBD Oils

2

Partnering with N.A. Largest Hemp Grower Working partnership will deliver about 30 million pounds of hemp to processing facilities in 2018



Experienced Leadership Team

Seasoned leadership team for large scale technology driven Companies

Scalable Operating Platform

Operations are completely scalable in all states and market sectors

Biopharmaceutical product development in CBD

Our technology can run 215,000+ tests in 1 hour allowing us to test new innovations and assure high product quality



Farms/clones/seed: OR, CO, largest hemp farm/greenhouse in AZ (UC)

Processing facilities – OR, AZ (UC) 550,000 sf - 75,000 sf

Extraction facilities – AZ 15,000 sf (UC)



services

hemp drying


hemp extractions & proprietary formulations utilizing patented software & technology 215,000 data points - Total Analysis Time:

1 hr./sample/screen



patentable products

Unique Hemp Products - Consistent Purity & Quality Control





technology




Adding Intelligence to Search

- Real time algorithm data services
- 63 variables to farmers and buyers offset volatility in the market
- Increases profitability
- Provides on-going data gathering/mining
- Developed by a member of the California Department of Food and Agriculture for over 20 years

- High speed search engine
- Massive database analysis
- Multiple key data searching 12 keys
- Real time indexing and
- Reduces index size by 2-12 orders of magnitude
- Self-learning can infer results outside data
- Mimics the human brain
- Proprietary CBD/Drug Interaction analysis
- Pre-FDA drug search analysis data developed
- Protein database & patient analysis
- studies expedited


revenues

Capital Raise - \$100M




target

Stable and Consistent Margin growth with 93% GM



Clones are taken from another 'mother' plant and thus the primary cost of the clone is water/sunshine/time and small amount of amortized building/labor costs

capex



proforma

	Investment	End Of 1st Year \$100,000,000	End Of 2nd Year	End Of 3rd Year	End Of 4th Year
Povonuo			(60)	(60)	
Revenue	Capital	(\$100,000,000)	(\$0)	(\$0)	(\$0)
Growth driven by acquisition, cloning and	Production	\$9,379,488	\$9,379,488	\$10,910,976	\$10,910,976
expansion of drying/extraction/product	Operating	\$4,707,626	\$6,385,583	\$8,679,485	\$11,823,705
specialization	Real Estate	\$16,650,000	\$0	\$16,650,000	\$0
Gross Margin	Real Estate	\$5,300,000	\$0	\$5,000,000	\$0
Growth driven by acquisition, cloning	Equipment	\$21,200,000	\$0	\$18,200,000	\$0
genetics, expansion of	Production	\$9 <i>,</i> 379,488	\$9,379 <i>,</i> 488	\$10,910,976	\$10,910,976
Irying/extraction/product specialization	Seed/Clones	\$10,792,002	\$2,011,872	\$2,011,872	\$2,011,872
EBIT	Total	(\$68,029,116)	(\$17,776,943)	(\$61,452,333)	(\$24,746,553)
Ebit before capital					
	Gross Revenue	\$376,932,329	\$622,574,442	\$768,370,015	\$1,031,156,508
	Operating Profit	\$308,903,213	\$604,797,499	\$706,917,682	\$1,006,409,955
	Valuation x15	\$4,633,548,195	\$9,071,962,485	\$10,603,765,230	\$ 15,096,149,325
	Valuation x40	\$12,356,128,520	\$24,191,899,960	\$28,276,707,280	\$40,256,398,200
	Valuation x100	\$30,890,321,300	\$60,479,749,900	\$70,691,768,200	\$100,640,995,500

R

G ex

S

Gr

ge dr

> E E

comparison valuations

(In \$millions)	Market	Enterprise	LT	M	EV /	EV /
Company	cap	value	Revenue	EBITDA	revenue	EBITDA
Canopy Growth	9,105	8,925	70	(26)	127.9x	nmf
Aurora Cannabis	5,652	5,584	42	(40)	133.0x	nmf
MedReleaf ¹	2,877	2,671	44	3	61.2x	1027.8x
Aphria	2,615	2,489	31	1	81.3x	1742.38
Cronos Group	1,700	1,674	7	(2)	257.0x	nmf
The Green Organic Dutchman Holdings	1,613	1,506	9.1	(19)	nmf	nmi
Hydropothecary	953	688	4	(4)	159.0x	nmi
CannTrust Holdings	921	911	26	22	35.7x	40.73
OrganiGram Holdings	717	635	10	(2)	60.8x	nmi
Emerald Health Therapeutics	570	483	1	(12)	434.8x	nmf
Supreme Cannabis	432	384	5	(7)	72.3x	nmf
Newstrike Resources	370	283	-	(10)	nmf	nmi
Maricann Group	261	235	3	(28)	87.9x	nmi
WeedMD ¹	196	156	3	(6)	60.0x	nmi
Emblem	175	115	3	(11)	37.5x	nmi
Sum	28,158	26,738	248	(141)	N/A	N/A
Mean (excl. low and high)	1,452	1,361	14	(9)	103.4x	1027.83
Median	921	688	5	(7)	81.3x	1027.88

tal IQ, Company Reports, PwC Analysis. Data as at June 20, 2018.

competition

What products do competitors offer? Are competitors making money?

7 distinct areas involved with Hemp-CBD oil(23%), Personal Care(23%), Industrial Applications(18%), Food(17%), Consumer Textiles(13%), Supplements(5%), and Other Consumer Products(2%). (*Hemp Business Journal estimates*)

Total sales for the U.S. Hemp industry in 2017 was \$820mm

- \$190mm for Hemp-Derived CBD products, \$181mm was for personal care products
- \$137mm was for Hemp Food products- snack food
- \$144mm was for Industrial Products led by the Automotive Industry

Growth is expected to be \$1.9 billion for 2018, with a 5 year CAGR of 14% (2018-2022) The U.S. is the largest importer of hemp products, which includes textiles from China, food and seed from Canada, and Industrials from Europe. So, it is fragmented, and subject to geo-political risk Hemp seed imports decreased 57% in 2017 from the all-time high of 39mm pounds in 2016. Estimates show a decrease of 20% in 2018.

Major competition

Hemp Only (Small)	Hemp, Inc (HEMP)	Charlotte's Web (CWEB)	Isodiol (ISOL)	CV Sciences (CVSI)	
Financials	52 wk. Range 0.0162 - 0.212 Revenue- negative \$5.1mm thru 6/18 EPS-N/A Shares Outstanding 3.3 bil (yes, 3.3 bil weighted out of 10.5bil authorized) Stock sits at 0.0286	52 wk Range 9.05 - 18.5 EPS 0.16 Volume 352,285 Market Cap 1.56B P/E Ratio 105.04 Shares Outstanding 92,846,395 Next Earnings Date <u>Nov 28, 2018</u>	Revenue 25.61M 52 wk. Range 2.4 - 21.4 EPS- 1.31 Volume 377,499 Market Cap 104.8M Average Vol. 5,264,041 Beta 0.72 1-Year Change- 7.14% Shares Outstanding 40,309,211	Prev. Close 5.6 Day's Range 4.91 - 5.75 Revenue 33.25M 52 wk Range 0.1575 - 9.2 EPS 0.03 Volume 1,485,625 Market Cap 509.3M Average Vol. (3m) 860,454 P/E Ratio 176.6 Beta 1.19 1-Year Change 2287.04% Shares Outstanding 90,945,896	
Market Cap	Unknown	\$1.5 billion	\$121.33	\$509.3 mm	

Hemp/Cannabis Aurora (ACB)		Canopy (CGC)	Tilray (TLRY)	Cronos (CRON)	
Hemp/Cannabis	Medical Marijuana, Inc. (MJNA)	Cannabis Sativa (CBDS)	The Green Organic Dutchman (TGODF)	Aurora (ACB)	

term sheet

- S.A.F.E structured simple agreement for future equity
- MFN Provision to Investor
- Pro Rata rights
- Specific term sheet available electronically
- Safe: MFN, no Cap, no Valuation discount detail sheet
- Safe: Pro Rata Right Side Letter